Optimi Health (OPTH) has made the third commercial shipment of 5mg psilocybin capsules for patients with treatment-resistant depression to Australia, the company said Monday.
Treatment-resistant depression refers to major depression that has not responded to multiple standard antidepressant treatments, according to a statement.
OPTH shares were trading 4.2% higher Monday morning.
Price: $4.26, Change: $+0.17, Percent Change: +4.16%